Pfizer Inc. (NYSE:PFE) Shares Purchased by Disciplined Equity Management Inc.

Disciplined Equity Management Inc. lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 1,047.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,410 shares of the biopharmaceutical company’s stock after acquiring an additional 2,200 shares during the period. Disciplined Equity Management Inc.’s holdings in Pfizer were worth $69,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Investment Advisory Services Inc. TX ADV increased its stake in Pfizer by 1.6% during the 3rd quarter. Investment Advisory Services Inc. TX ADV now owns 20,097 shares of the biopharmaceutical company’s stock valued at $667,000 after buying an additional 325 shares during the period. Trifecta Capital Advisors LLC increased its stake in shares of Pfizer by 3.7% during the third quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock valued at $305,000 after acquiring an additional 325 shares during the period. Powers Advisory Group LLC raised its holdings in Pfizer by 2.4% during the third quarter. Powers Advisory Group LLC now owns 13,759 shares of the biopharmaceutical company’s stock worth $456,000 after purchasing an additional 329 shares in the last quarter. Confluence Wealth Services Inc. lifted its position in Pfizer by 0.5% in the third quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock worth $2,158,000 after purchasing an additional 342 shares during the period. Finally, Carr Financial Group Corp boosted its stake in Pfizer by 3.3% during the 3rd quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock valued at $344,000 after purchasing an additional 355 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Down 0.2 %

NYSE PFE traded down $0.06 during trading on Wednesday, reaching $26.26. The company’s stock had a trading volume of 24,501,011 shares, compared to its average volume of 41,887,898. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $148.70 billion, a PE ratio of 72.94, a PEG ratio of 1.18 and a beta of 0.61. Pfizer Inc. has a 1-year low of $25.23 and a 1-year high of $40.37. The business has a 50-day moving average price of $27.05 and a 200-day moving average price of $28.50.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s revenue was down 41.3% compared to the same quarter last year. During the same period last year, the business earned $1.14 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.40%. Pfizer’s dividend payout ratio is currently 466.67%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on PFE shares. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Guggenheim began coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Eleven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average target price of $36.33.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.